Finance

Lists
Why is PHAT up 3,35%?
Dive Deeper
PHAT:NASDAQ
Phathom Pharmaceuticals Inc
5,25 $
+3,35%
(+0,17) 1D
5,25 $
0,00% (0,00)
After hours
Closed: 6 қар., 16:00:00 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PHAT...
Open
5,26 $
High
5,30 $
Low
5,04 $
Mkt. cap
426,78 млн
Avg. vol.
1,65 млн
Volume
1,77 млн
52-wk high
18,31 $
52-wk low
5,02 $
EPS
-1,03 $
Beta
0,69
Shares outstanding
81,29 млн
No. of employees
371
Open
5,26 $
High
5,30 $
Low
5,04 $
Mkt. cap
426,78 млн
Avg. vol.
1,65 млн
Volume
1,77 млн
52-wk high
18,31 $
52-wk low
5,02 $
EPS
-1,03 $
Beta
0,69
Shares outstanding
81,29 млн
No. of employees
371
News stories
From web sources and news partners
About Phathom Pharmaceuticals Inc
CEO-
Employees371
Founded2018
HeadquartersФлорхам Парк, Нью-Джерси, Америка Құрама Штаттары
SectorHealth Care
IndustryPharmaceutical industry
Analyst ratings
Based on 6 analysts giving stock ratings to PHAT in the past 3 months
Strong buy
Buy
5
Hold
1
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for PHAT in the last 3 months.
Highest
Current 5,25 $
26,00 $ (+395,24%)
Average
16,90 $ (+221,90%)
Lowest
7,50 $ (+42,86%)
Analyst
Recommendation
Action
Price target
Projected
Date
Daniel Clark
Leerink Partners
Hold
Maintained
7,50 $
+42,9%
11/02/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
22,00 $
+319%
10/29/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
26,00 $
+395,2%
10/30/2026
Jenna Davidner
Barclays
Buy
Maintained
14,00 $
+166,7%
10/30/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
-
-
10/23/2026
Chase Knickerbocker
Craig-Hallum
Buy
Maintained
15,00 $
+185,7%
10/21/2026
Martin Auster
Raymond James
Buy
Maintained
21,00 $
+300%
07/31/2026
Joseph Stringer
Needham
Buy
Maintained
22,00 $
+319%
07/30/2026
Paul Choi
Goldman Sachs
Hold
Maintained
-
-
04/30/2026
Last report
2026 ж. 29 қаз.
Fiscal period
Q3 2026
0,04 $ / 0,03 $
+39,86%beat
Revenue / Est. (USD)
84,72 млн / 84,82 млн
-0,12%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
Revenue
Cost of goods sold
Cost of revenue
Research and development expenses
Total research and development expenses
Selling, general, and admin expenses
Operating expense
Total operating expenses
Operating income
Other non operating income
EBT including unusual items
EBT excluding unusual items
Income tax expense
Effective tax rate
Other operating expenses
Net income
Net profit margin
Earnings per share
Interest and investment income
Interest expense
Net interest expenses
Depreciation and amortization charges
EBITDA
Gain or loss from assets sale
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google қолданбалары